Replies to post #76383 on Biotech Values

[DewDiligence]

RDEA: Valeant has an option to license this compound [RDEA-806] post phase 2B and pre phase 3.

For the HIV program (as opposed to the gout program), this option may be moot insofar as RDEA does not plan to start a phase-2b trial without a partner.